Key result
In a rat arterial thrombolysis model, BCH-2763 combined with tPA significantly shortened time to lysis (0.5 vs 66.3 min) and resulted in a lower aPTT fold increase compared to standard heparin.
Why the study?
Does BCH-2763 combined with tPA improve thrombolysis and reduce bleeding compared to standard heparin or other direct thrombin inhibitors in a rat arterial thrombolysis model?
Population
Rat carotid arterial thrombolysis model (FeCl3-induced injury)
Comparison
BCH-2763 combined with tissue plasminogen… vs Standard heparin, r-hirudin, hirulog, or tPA alone
Design
Preclinical
Authors
Loading...
Supports BCH-2763 evaluation in larger models; leaves open clinical translation for arterial thrombolysis.
Does BCH-2763 combined with tPA improve thrombolysis and reduce bleeding compared to standard heparin or other direct thrombin inhibitors in a rat arterial thrombolysis model?
Absolute Event Rate: 0.5% vs 66.3%
p-value: p=<0.01
In a rat model, the novel direct thrombin inhibitor BCH-2763 combined with tPA achieved faster thrombolysis with less bleeding and aPTT prolongation compared to standard heparin or other direct thrombin inhibitors.
Deschênes et al. (1998) studied Arterial thrombolysis. BCH-2763 + tPA vs. Standard heparin, r-hirudin, hirulog, or tPA alone was evaluated on Time to lysis (min) (p=<0.01). In a rat arterial thrombolysis model, BCH-2763 combined with tPA significantly shortened time to lysis (0.5 vs 66.3 min) and resulted in a lower aPTT fold increase compared to standard heparin.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: